ARCT

#3502
Arcturus Therapeutics Holdings Inc. Common Stock
8.75 USD
+3.43%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
8.63
8.75
Rango anual
5.86
24.14
Cambio diario
+3.43%
Variación mensual
+28.87%
Variación en los últimos 6 meses
-58.90%
Cambio anual
-15.05%
Cierres anteriores
8.46
Abrir
8.64
Bid
Ask
Mínimo
8.63
High
8.75
Volumen
22
Ver el calendario completo

Financials

Visión general Informes Estadísticas
Trimestre Año
  • Market Capitalization 248.7 M
  • Employee 111
  • Founded 2013
  • CEO Joseph E. Payne
  • Website www.arcturusrx.com
  • Headquarter Delaware, United States
  • FIGI BBG00NNW8JK1
  • Industry Technology
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
-2.55
Relación precio/flujo de caja
2.05

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA, messenger RNA, gene editing RNA, DNA, antisense oligonucleotides, and microRNA. The company develops RNA therapeutics for the treatment of rare diseases such as ornithine transcarbamylase deficiency, and respiratory diseases such as cystic fibrosis. Vaccine medicines include a vaccine candidate for COVID-19 and an influenza vaccine in the preclinical development phase. The vaccine for COVID-19 was authorised in Japan in 2023 and the European Union in 2025.

Noticias